Aerie Pharmaceuticals (AERI) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($6.96 million) and the uptick to downtick ratio was 0.28. The transaction value on upticks was $2.64 million and on downticks, the transaction value was $9.6 million. The transaction value of block trades during downticks was $7.49 million. The money flow was negative ($7.49 million), indicating the traders were booking profit on the price strength. Aerie Pharmaceuticals (AERI) rose $1 at $19.43, during intraday Monday , a rise of 5.43% over the previous days close.
Shares of Aerie Pharmaceuticals, Inc. rose by 6.88% in the last five trading days and 11.09% for the last 4 weeks. Aerie Pharmaceuticals, Inc. is up 39.99% in the last 3-month period. Year-to-Date the stock performance stands at -20.21%.
Aerie Pharmaceuticals (NASDAQ:AERI): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.49 and $18.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $20.02. The buying momentum continued till the end and the stock did not give up its gains. It closed at $19.43, notching a gain of 5.43% for the day. The total traded volume was 835,590 . The stock had closed at $18.43 on the previous day.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Aerie Pharmaceuticals Inc, Cagle Gerald D. had purchased shares worth of $84,743 in a transaction dated on February 4, 2015. A total of 4,646 shares were purchased at a price of $18.24 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Companys primary product candidates, triple-action Rhopressa and quadruple-action Roclatan, are once-daily eye drops. The Companys product candidate, once-daily, quadruple-action Roclatan, is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET), which are both biochemical targets for lowering intraocular pressure (IOP). The Companys Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533, its second-generation ROCK/NET inhibitor.